The revised joint guidelines.
There is a wealth of scientific evidence that lifestyle interventions and the use of drug therapies in patients with coronary heart disease (CHD) and individuals at high risk for developing CHD can reduce cardiovascular morbidity and mortality. In the revised guidelines of the European Joint Task Force for the prevention of CHD in clinical practice, these individuals remain the priority for prevention. The new guidelines have been formulated as a result of evidence from numerous epidemiological, observational and clinical trials and define specific goals of therapy for the management of lipids, blood pressure and diabetes. The intensity of lifestyle intervention and need for drug therapy should be determined by the absolute risk of a major ischemic event, based on an assessment of all risk factors. Implementation of these recommendations in clinical practice will ensure a common approach to CHD prevention throughout Europe and improve patients' quality of life.
Faergeman
O
O
Department of Internal Medicine and Cardiology, Faculty of Health Sciences, Aarhus University Hospital AAS, Tage-Hansensgade 2, DK-8000 Aarhus C, Denmark.
D001794:Blood Pressure / Q000502:physiology; D002784:Cholesterol / Q000502:physiology; D003327:Coronary Disease / Q000503:physiopathology / Q000628:therapy*; D003920:Diabetes Mellitus / Q000503:physiopathology; D005260:Female; D017408:Guidelines as Topic / Q000592:standards*; D015438:Health Behavior; D006801:Humans; D008297:Male; D012307:Risk Factors
D002784:Cholesterol